TWThomas Wendl

Thomas Wendl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Wendl has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing Open‐Source Solutions: Insights From the First Open Systems Pharmacology ( OSP ) Community Conference

    by André Dallmann, Denise Feick, Pavel Balazki, Salih Benamara, Rolf Burghaus, Marylore Chenel, Siak‐Leng Choi, Henrik Cordes, Mariana Guimarães, Abdullah Hamadeh, et al.

    In 2017, the free and open‐source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into a diverse network of stakeholders committed to advancing open‐source solutions for model‐informed drug development (MIDD). In this context, the first OSP Community Conference was hosted by Novartis in Basel, Switzerland, on October 7–8, 2024, which gathered over 100 attendees from more than 40 institutions. This perspective synthesizes key insights from the conference.


  • A quantification of gastric and duodenal fluid volumes in older adults using MRI

    by Cleo Demeester, Matthias Van der Veken, Joachim Brouwers, Ragna Vanslembrouck, André Dallmann, Thomas Wendl, Patrick Augustijns


  • Eine vergleichende In-vitro-Studie zur Haftfestigkeit von mit Kleber vorbeschichteten und nicht vorbeschichteten Brackets

    by Thomas Wendl, Brigitte Wendl

    Zusammenfassung: In dieser Arbeit wurde die Haftfestigkeit vorbeschichteter Brackets mit Brackets, bei denen der Kleber erst beim Bonding auf die Bracketbasis aufgebracht wird, verglichen. Die Haftfestigkeit der geklebten Brackets am Schmelz wurde mittels Abscherversuche mit einer Instronmessmaschine (Vorschubgeschwindigkeit 0,5 mm/Min) ermittelt und der am Schmelz verbliebene Kleberanteil mit dem modifizierten Adhesive Remnant Index=ARI (Stereomikroskop der Fa. Zeiss) bestimmt. Die Auswertung erfolgte mit dem SPSS-Programm. Beim Vergleich zweier Mittelwerte wurde der T-Test für unabhängige Stichproben angewandt und das Signifikanzniveau auf p90% des Klebers auf der Schmelzoberfläche. Das APC System zeigte auch ein ähnliches Frakturmuster, dennoch war ein etwas besserer Verbund Kleber / Bracketbasis zu erkennen.

  • Open Access

    Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic Exposure

    by Soyoung Kim, Brian Cicali, Michelle Pressly, Lais Da Silva, Thomas Wendl, Valvanera Vozmediano, Stephan Schmidt, Rodrigo Cristofoletti

    Levonorgestrel (LNG) is a progestin used in many contraceptive formulations, including subcutaneous implants. There is an unmet need for developing long-acting formulations for LNG. To develop long-acting formulations, release functions need to be investigated for LNG implant. Therefore, a release model was developed and integrated into an LNG physiologically-based pharmacokinetic (PBPK) model. Utilizing a previously developed LNG PBPK model, subcutaneous administration of 150 mg LNG was implemented into the modeling framework. To mimic LNG release, ten functions incorporating formulation-specific mechanisms were explored. Release kinetic parameters and bioavailability were optimized using Jadelle® clinical trial data (n = 321) and verified using two additional clinical trials (n = 216). The First-order release and Biexponential release models showed the best fit with observed data, the adjusted R-squared (R2) value is 0.9170. The maximum released amount is approximately 50% of the loaded dose and the release rate is 0.0009 per day. The Biexponential model also showed good agreement with the data (adjusted R2 = 0.9113). Both models could recapitulate observed plasma concentrations after integration into the PBPK simulations. First-order and Biexponential release functionality may be useful in modeling subcutaneous LNG implants. The developed model captures central tendency of the observed data as well as variability of release kinetics. Future work focuses on incorporating various clinical scenarios into model simulations, including drug-drug interactions and a range of BMIs.


  • Open Access

    Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone

    by Thomas Wendl, Sebastian Frechen, Michael Gerisch, Roland Heinig, Thomas Eissing

    Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist that recently demonstrated its efficacy to delay chronic kidney disease (CKD) progression and reduce cardiovascular events in patients with CKD and type 2 diabetes. Here, we report the development of a physiologically‐based pharmacokinetic (PBPK) model for finerenone and its application as a victim drug of cytochrome P450 3A4 (CYP3A4)‐mediated drug‐drug interactions (DDIs) using the open‐source PBPK platform PK‐Sim, which has recently been qualified for this application purpose. First, the PBPK model for finerenone was developed using physicochemical, in vitro, and clinical (including mass balance) data. Subsequently, the finerenone model was validated regarding the contribution of CYP3A4 metabolism to total clearance by comparing to observed data from dedicated clinical interaction studies with erythromycin (simulated geometric mean ratios of the area under the plasma concentration‐time curve [AUCR] of 3.46 and geometric mean peak plasma concentration ratios [CmaxRs] of 2.00 vs. observed of 3.48 and 1.88, respectively) and verapamil (simulated AUCR of 2.91 and CmaxR of 1.86 vs. observed of 2.70 and 2.22, respectively). Finally, the finerenone model was applied to predict clinically untested DDI studies with various CYP3A4 modulators. An AUCR of 6.31 and a CmaxR of 2.37 was predicted with itraconazole, of 5.28 and 2.25 with clarithromycin, 1.59 and 1.40 with cimetidine, 1.57 and 1.38 with fluvoxamine, 0.19 and 0.32 with efavirenz, and 0.07 and 0.14 with rifampicin. This PBPK analysis provides a quantitative basis to guide the label and clinical use of finerenone with concomitant CYP3A4 modulators.